Fulgent Genetics (FLGT) Gross Profit (2015 - 2026)

Fulgent Genetics has reported Gross Profit for 12 years, with the latest figure at $25.7 million in Q2 2026.

• Quarterly Gross Profit fell 25.43% year-over-year to $25.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $115.3 million (down 5.06% YoY) and the FY2025 annual result came in at $130.9 million, up 22.07% from the prior year.
• Gross Profit improved to $25.7 million in Q2 2026 per FLGT's latest filing, from $21.5 million in the prior quarter.
• Over five years, Gross Profit peaked at $242.5 million in Q1 2022 and troughed at $13.0 million in Q4 2022.
• A 5-year average of $42.0 million and a median of $27.6 million in 2024 frame the typical range for Gross Profit.
• The sharpest annual moves came in 2022 and 2023: Gross Profit tumbled 93.15% in 2022, then jumped 94.26% in 2023.
• Over 5 years, Gross Profit stood at $13.0 million in 2022, then surged by 94.26% to $25.2 million in 2023, then rose by 26.24% to $31.8 million in 2024, then increased by 2.3% to $32.6 million in 2025, then decreased by 21.19% to $25.7 million in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $25.7 million, $21.5 million, and $32.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.